Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE4
Total Enrollment
36 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-03-02
Study Completion Date
2022-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Levomilnacipran is an antidepressant currently approved in Canada to treat Major Depressive Disorder (MDD). Thirty-six healthy male participants will receive escalating doses of levomilnacipran, duloxetine, or placebo every 7 days (+/- 1 day) throughout a 20 - 28 day period. After each dose escalation study participants will be asked to come to the clinic to conduct the necessary tests - these will include tyramine pressor tests as well as blood draws. The results of this study will allow the investigators to determine the dose(s) of levomilnacipran at which reuptake inhibition of norepinephrine and serotonin (chemicals utilized by nerve cells to transmit information to other cells) is achieved.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder
NCT03569475
Major Depressive Disorder
COMPLETED
PHASE3
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder
NCT01377194
Major Depressive Disorder
COMPLETED
PHASE3
Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder
NCT02431806
Major Depressive Disorder
COMPLETED
PHASE3
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
NCT00969709
Major Depressive Disorder
COMPLETED
PHASE3
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
NCT01034462
Major Depressive Disorder
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Levomilnacipran (Fetzima) is the active enantiomer of milnacipran (Ixel, Savella) for norepinephrine (NE) and serotonin (5-hydroxytryptamine, 5-HT) reuptake. It has an approximate eight-fold greater affinity for the human NE transporter than for the 5-HT transporter. This signifies that the NE transporter may be engaged to a much greater degree than the 5-HT transporter at various doses, especially at lower regimens. As such, levomilnacipran represents the mirror antidepressant medication of venlafaxine and duloxetine since at their minimal effective doses, these medications are selective inhibitors of 5-HT reuptake and it is not until daily regimens are doubled or tripled that the NE transporter gets engaged.
Levomilnacipran is effective clinically in patients with major depressive disorder (MDD) at doses ranging between 40 and 120 mg/day. Given this wide effective dose range, it appears essential to determine the in vivo potency of levomilnacipran and the dose at which it starts inhibiting 5-HT in relation to NE reuptake in humans.
The current investigators have studied the NE reuptake blocking properties of antidepressants in both healthy volunteers and patients with depression using tyramine pressor tests. This peripheral model of adrenergic function involves administration of repeated intravenous injections of tyramine and measurement of transient increases in systolic blood pressure (SBP) that occur after a tyramine load. This approach has led to dose-dependent SBP increases that are reliably reproduced one week apart in healthy volunteers who received placebo which supports the use of the tyramine pressor test to assess the functional capacity of different medication regimens to inhibit NE reuptake at steady state levels. Serotonin reuptake has been extensively studied in human participants using the blood platelet model. In this assay, whole blood 5-HT and/or platelet content is determined before and after giving reuptake inhibitors. Since the 5-HT transporter is similar on 5-HT neurons in the brain and on platelets, the degree of 5-HT depletion in the blood can be used as a measure of 5-HT reuptake blockade in the brain. Together, these experimental approaches will identify the potency of levomilnacipran for NE and 5-HT reuptake inhibition.
The purpose of this study is to determine the potency of levomilnacipran required to inhibit NE and 5-HT reuptake in healthy male participants across the effective dose range of the medication (40-120 mg/day).
Participants Healthy male participants will receive escalating doses of levomilnacipran, duloxetine, or placebo every 4-7 days throughout a 14-23 day period. The tyramine pressor procedure will be used to identify the dose at which these medications inhibit norepinephrine reuptake. Serotonin reuptake inhibition will be estimated from whole blood serotonin concentrations. Tyramine testing and blood draws will occur at baseline (prior to medication administration) and 4 days after each dose escalation.
Participants will be assigned to one of 3 groups: levomilnacipran, duloxetine or placebo. The duration of study treatment for participants in the first 2 groups will range from 22-32 days. These participants will receive escalating doses of levomilnacipran or duloxetine over a period of 14-23 days followed by down-titrated doses over the next 8 days. The investigators will offer a flexible interval for dose escalation in participants receiving levomilnacipran and duloxetine to minimize side effects, improve tolerability, and maximize subject retention. Participants in the placebo group will receive the levomilnacipran-matched placebo capsule for 14 days.
Specific aim The objective of this study is to assess the norepinephrine and serotonin reuptake inhibition capacities of levomilnacipran using the tyramine pressor procedure and blood platelet model respectively. Two control groups will be included to demonstrate the validity of the two experimental approaches, an active comparator group, and a placebo group. Therefore, there will be three treatment arms: 1) 12 participants will be administered escalating doses of levomilnacipran, 2) 12 participants will be administered escalating doses of duloxetine, and 3) 12 participants will receive levomilnacipran placebo-match capsules. Duloxetine will be used as an active comparator as it is an established 5-HT reuptake inhibitor and a potentially effective NE reuptake inhibitor.
Assessments to be Performed Pharmacodynamic and safety evaluations: At each visit, a catheter will be placed in the subject's antecubital vein. The participant will lie down and remain supine until his pulse is determined to be stable (+/- approximately 5 bpm) over two consecutive measurements made a minimum of 10 minutes apart. The subject's heart rate and blood pressure will be recorded from the arm contralateral to the catheter. Blood samples will be drawn from the catheter while the participant remains supine. The participant's heart rate and blood pressure will again be recorded from the arm contralateral to the catheter.
Plasma drug levels: Plasma concentrations of levomilnacipran and duloxetine will be determined from supine blood samples after each dose change to ensure that potentially aberrant results are not due to poor medication compliance.
Whole blood serotonin assay: Whole blood 5-HT concentrations will be determined from supine blood samples collected at regular visits.
Evaluation of tyramine pressor response: After the supine blood samples are drawn, the tyramine infusion procedure will proceed as follows: 1) The participant will be connected to the cardiac monitor apparatus, which automatically monitors blood pressure and heart rate. 2) The participant will lie down and remain supine until his pulse is determined to be stable over two consecutive measurements made a minimum of 10 minutes apart. 3) A first small dose of tyramine (0.5 mg) will be administered intravenously to rule out the presence of pheochromocytoma. Pheochromocytoma is a small neuroendocrine tumour which can cause elevated secretion of catecholamines leading to raised blood pressure, palpitations and headaches. This condition would not be detected through physical exam or laboratory tests. This dose is not expected to produce any significant change in the cardiovascular parameters measured. Ten minutes after the participant receives the 0.5 mg tyramine dose, the effects of two fixed doses of intravenous tyramine on systolic blood pressure will be assessed. First, a 4 mg dose of tyramine will be administered. Five minutes after the subject's blood pressure returns to normal, a 6 mg dose will be administered. 4) Heart rate, systolic and diastolic blood pressure will be recorded every 2 minutes for at least 10 minutes after the injection, or 5 minutes after the return of baseline blood pressure and heart rate, whichever is longer.
Safety/Monitoring procedures: A physician and research nurse coordinator will be present during the entire tyramine procedure, and participants will remain on the unit for a further 15 min after all Tyramine Pressor Test procedures have completed for monitoring. There is access to an automated external defibrillator (AED), and a crash cart with supporting staff in case of emergency.
Levomilnacipran is effective clinically in patients with major depressive disorder (MDD) at doses ranging between 40 and 120 mg/day. Given this wide effective dose range, it appears essential to determine the in vivo potency of levomilnacipran and the dose at which it starts inhibiting 5-HT in relation to NE reuptake in humans.
The current investigators have studied the NE reuptake blocking properties of antidepressants in both healthy volunteers and patients with depression using tyramine pressor tests. This peripheral model of adrenergic function involves administration of repeated intravenous injections of tyramine and measurement of transient increases in systolic blood pressure (SBP) that occur after a tyramine load. This approach has led to dose-dependent SBP increases that are reliably reproduced one week apart in healthy volunteers who received placebo which supports the use of the tyramine pressor test to assess the functional capacity of different medication regimens to inhibit NE reuptake at steady state levels. Serotonin reuptake has been extensively studied in human participants using the blood platelet model. In this assay, whole blood 5-HT and/or platelet content is determined before and after giving reuptake inhibitors. Since the 5-HT transporter is similar on 5-HT neurons in the brain and on platelets, the degree of 5-HT depletion in the blood can be used as a measure of 5-HT reuptake blockade in the brain. Together, these experimental approaches will identify the potency of levomilnacipran for NE and 5-HT reuptake inhibition.
The purpose of this study is to determine the potency of levomilnacipran required to inhibit NE and 5-HT reuptake in healthy male participants across the effective dose range of the medication (40-120 mg/day).
Participants Healthy male participants will receive escalating doses of levomilnacipran, duloxetine, or placebo every 4-7 days throughout a 14-23 day period. The tyramine pressor procedure will be used to identify the dose at which these medications inhibit norepinephrine reuptake. Serotonin reuptake inhibition will be estimated from whole blood serotonin concentrations. Tyramine testing and blood draws will occur at baseline (prior to medication administration) and 4 days after each dose escalation.
Participants will be assigned to one of 3 groups: levomilnacipran, duloxetine or placebo. The duration of study treatment for participants in the first 2 groups will range from 22-32 days. These participants will receive escalating doses of levomilnacipran or duloxetine over a period of 14-23 days followed by down-titrated doses over the next 8 days. The investigators will offer a flexible interval for dose escalation in participants receiving levomilnacipran and duloxetine to minimize side effects, improve tolerability, and maximize subject retention. Participants in the placebo group will receive the levomilnacipran-matched placebo capsule for 14 days.
Specific aim The objective of this study is to assess the norepinephrine and serotonin reuptake inhibition capacities of levomilnacipran using the tyramine pressor procedure and blood platelet model respectively. Two control groups will be included to demonstrate the validity of the two experimental approaches, an active comparator group, and a placebo group. Therefore, there will be three treatment arms: 1) 12 participants will be administered escalating doses of levomilnacipran, 2) 12 participants will be administered escalating doses of duloxetine, and 3) 12 participants will receive levomilnacipran placebo-match capsules. Duloxetine will be used as an active comparator as it is an established 5-HT reuptake inhibitor and a potentially effective NE reuptake inhibitor.
Assessments to be Performed Pharmacodynamic and safety evaluations: At each visit, a catheter will be placed in the subject's antecubital vein. The participant will lie down and remain supine until his pulse is determined to be stable (+/- approximately 5 bpm) over two consecutive measurements made a minimum of 10 minutes apart. The subject's heart rate and blood pressure will be recorded from the arm contralateral to the catheter. Blood samples will be drawn from the catheter while the participant remains supine. The participant's heart rate and blood pressure will again be recorded from the arm contralateral to the catheter.
Plasma drug levels: Plasma concentrations of levomilnacipran and duloxetine will be determined from supine blood samples after each dose change to ensure that potentially aberrant results are not due to poor medication compliance.
Whole blood serotonin assay: Whole blood 5-HT concentrations will be determined from supine blood samples collected at regular visits.
Evaluation of tyramine pressor response: After the supine blood samples are drawn, the tyramine infusion procedure will proceed as follows: 1) The participant will be connected to the cardiac monitor apparatus, which automatically monitors blood pressure and heart rate. 2) The participant will lie down and remain supine until his pulse is determined to be stable over two consecutive measurements made a minimum of 10 minutes apart. 3) A first small dose of tyramine (0.5 mg) will be administered intravenously to rule out the presence of pheochromocytoma. Pheochromocytoma is a small neuroendocrine tumour which can cause elevated secretion of catecholamines leading to raised blood pressure, palpitations and headaches. This condition would not be detected through physical exam or laboratory tests. This dose is not expected to produce any significant change in the cardiovascular parameters measured. Ten minutes after the participant receives the 0.5 mg tyramine dose, the effects of two fixed doses of intravenous tyramine on systolic blood pressure will be assessed. First, a 4 mg dose of tyramine will be administered. Five minutes after the subject's blood pressure returns to normal, a 6 mg dose will be administered. 4) Heart rate, systolic and diastolic blood pressure will be recorded every 2 minutes for at least 10 minutes after the injection, or 5 minutes after the return of baseline blood pressure and heart rate, whichever is longer.
Safety/Monitoring procedures: A physician and research nurse coordinator will be present during the entire tyramine procedure, and participants will remain on the unit for a further 15 min after all Tyramine Pressor Test procedures have completed for monitoring. There is access to an automated external defibrillator (AED), and a crash cart with supporting staff in case of emergency.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
None (i.e. Healthy Volunteers)
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
SINGLE
Participants
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Levomilnacipran
Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
Group Type
EXPERIMENTAL
Levomilnacipran
Intervention Type
DRUG
Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
Duloxetine (Cymbalta)
Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
Group Type
ACTIVE_COMPARATOR
Duloxetine
Intervention Type
DRUG
Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
Levomilnacipran Placebo-matched capsules
Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
Group Type
PLACEBO_COMPARATOR
Placebos
Intervention Type
DRUG
Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levomilnacipran
Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
Intervention Type
DRUG
Duloxetine
Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
Intervention Type
DRUG
Placebos
Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Fetzima
Cymbalta
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male participants between 18 and 40 years-old
* Written informed consent signed by the participant
* Written informed consent signed by the participant
Exclusion Criteria
* Lifetime personal history of diagnosis of major depressive disorder according to the DSM-V (American Psychiatric Association, 2013) using the Structured Clinical Interview for DSM-V Axis I Disorders, Research Version, Non-patient Edition (SCID-5-RV for DSM-V; First et al., 2015)
* A history of suicidal ideation and behaviour, including self-harm and/or harm to others.
* A history of substance abuse and/or dependence.
* A positive drug screen for illicit drugs
* Substantial alcohol use
* Current use of Monoamine Oxidase Inhibitors (MAOIs), including the antibiotic linezolid and the thiazine dye methylthioninium chloride (methylene blue)
* Current use of serotonin-precursors (such as L-tryptophan, oxitriptan)
* Current use of serotonergic drugs (triptans, certain tricyclic antidepressants, lithium, tramadol, St. John's Wort)
* Concomitant use of NSAIDS, ASA, and other anticoagulants.
* Current use of Thioridazine
* Current use of CYP1A2 Inhibitors
* Current use of Triptans (5HT1 Agonists)
* Blood pressure greater than 140/90 and/or a pulse rate greater than 90 bpm
* Recent history of myocardial infarction, cerebrovascular accident, cardiac arrhythmias, or unstable heart disease.
* Evidence of significant physical illness contraindicating the use of levomilnacipran and duloxetine found on the physical exam or in the laboratory data obtained during the first week of the study
* Current use of medication that may affect voiding (ie- anticholinergics)
* History of obstructive urinary disorders and dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.
* History of Stevens-Johnson Syndrome and Erythema multiforme.
* Diabetes Type I and II
* Fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency.
* Hepatic Impairment
* Uncontrolled narrow-angle glaucoma
* Severe renal impairment
* History of seizure disorder
* Anatomically narrow ocular angles.
* Osteoporosis or major risk for bone fractures.
* A history of suicidal ideation and behaviour, including self-harm and/or harm to others.
* A history of substance abuse and/or dependence.
* A positive drug screen for illicit drugs
* Substantial alcohol use
* Current use of Monoamine Oxidase Inhibitors (MAOIs), including the antibiotic linezolid and the thiazine dye methylthioninium chloride (methylene blue)
* Current use of serotonin-precursors (such as L-tryptophan, oxitriptan)
* Current use of serotonergic drugs (triptans, certain tricyclic antidepressants, lithium, tramadol, St. John's Wort)
* Concomitant use of NSAIDS, ASA, and other anticoagulants.
* Current use of Thioridazine
* Current use of CYP1A2 Inhibitors
* Current use of Triptans (5HT1 Agonists)
* Blood pressure greater than 140/90 and/or a pulse rate greater than 90 bpm
* Recent history of myocardial infarction, cerebrovascular accident, cardiac arrhythmias, or unstable heart disease.
* Evidence of significant physical illness contraindicating the use of levomilnacipran and duloxetine found on the physical exam or in the laboratory data obtained during the first week of the study
* Current use of medication that may affect voiding (ie- anticholinergics)
* History of obstructive urinary disorders and dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.
* History of Stevens-Johnson Syndrome and Erythema multiforme.
* Diabetes Type I and II
* Fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency.
* Hepatic Impairment
* Uncontrolled narrow-angle glaucoma
* Severe renal impairment
* History of seizure disorder
* Anatomically narrow ocular angles.
* Osteoporosis or major risk for bone fractures.
Minimum Eligible Age
18 Years
Maximum Eligible Age
40 Years
Eligible Sex
MALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Sponsor Role
collaborator
University of Ottawa
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pierre Blier
Endowed Research Chair and Director of Mood Disorders Research Unit
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre Blier, MD
Role: PRINCIPAL_INVESTIGATOR
The Royal's Institute of Mental Health Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Mental Health Research, Royal Ottawa Mental Health Centre
Ottawa, Ontario, Canada
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Canada
References
Explore related publications, articles, or registry entries linked to this study.
Asnis GM, Henderson MA. Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatr Dis Treat. 2015 Jan 9;11:125-35. doi: 10.2147/NDT.S54710. eCollection 2015.
Reference Type
BACKGROUND
Auclair AL, Martel JC, Assie MB, Bardin L, Heusler P, Cussac D, Marien M, Newman-Tancredi A, O'Connor JA, Depoortere R. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013 Jul;70:338-47. doi: 10.1016/j.neuropharm.2013.02.024. Epub 2013 Mar 13.
Reference Type
BACKGROUND
Blier P, Saint-Andre E, Hebert C, de Montigny C, Lavoie N, Debonnel G. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. Int J Neuropsychopharmacol. 2007 Feb;10(1):41-50. doi: 10.1017/S1461145705006395. Epub 2006 May 11.
Reference Type
BACKGROUND
Aldosary F, Norris S, Tremblay P, James JS, Ritchie JC, Blier P. Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder. Int J Neuropsychopharmacol. 2022 Apr 19;25(4):283-292. doi: 10.1093/ijnp/pyab086.
Reference Type
BACKGROUND
Debonnel G, Saint-Andre E, Hebert C, de Montigny C, Lavoie N, Blier P. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol. 2007 Feb;10(1):51-61. doi: 10.1017/S1461145705006413. Epub 2006 May 11.
Reference Type
BACKGROUND
First, M.B., Williams, J.B.W., Karg, R.S., & Spitzer, R.L. (2015). Structured clinical interview for DSM-5-research version. Arlington: American Psychiatric Association.
Reference Type
BACKGROUND
Gobbi G, Slater S, Boucher N, Debonnel G, Blier P. Neurochemical and psychotropic effects of bupropion in healthy male subjects. J Clin Psychopharmacol. 2003 Jun;23(3):233-9. doi: 10.1097/01.jcp.0000084023.22282.03.
Reference Type
BACKGROUND
Turcotte JE, Debonnel G, de Montigny C, Hebert C, Blier P. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001 May;24(5):511-21. doi: 10.1016/S0893-133X(00)00220-7.
Reference Type
BACKGROUND
Vincent S, Bieck PR, Garland EM, Loghin C, Bymaster FP, Black BK, Gonzales C, Potter WZ, Robertson D. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation. 2004 Jun 29;109(25):3202-7. doi: 10.1161/01.CIR.0000130847.18666.39. Epub 2004 Jun 7.
Reference Type
BACKGROUND
Nikolitch K, Phillips JL, Daniels S, Blier P. Levomilnacipran, but Not Duloxetine, Inhibits Serotonin and Norepinephrine Reuptake Throughout Its Therapeutic Range. J Clin Psychiatry. 2025 Aug 25;86(3):25m15867. doi: 10.4088/JCP.25m15867.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REB2017004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder
NCT02288325
COMPLETED
PHASE4
Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder
NCT01148472
COMPLETED
PHASE4
A Study of Patients With Major Depressive Disorder and Residual Apathy
NCT00985504
COMPLETED
PHASE4
Effects of Antidepressants on Sexual Functioning
NCT00051259
COMPLETED
PHASE3
Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression
NCT00200902
COMPLETED
PHASE4
Memory Functioning and Antidepressant Treatment
NCT00296933
COMPLETED
PHASE3
Escitalopram in Adult Patients With Major Depressive Disorder
NCT00668525
COMPLETED
PHASE3
A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression
NCT01814085
COMPLETED
PHASE4
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
NCT00252356
COMPLETED
PHASE3
A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom
NCT01870843
COMPLETED
PHASE4
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
NCT00252330
COMPLETED
PHASE3
Study of Escitalopram in Adult Patients With Major Depressive Disorder
NCT00108979
COMPLETED
PHASE3
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
NCT05017311
RECRUITING
PHASE4
Escitalopram in Depressive Patients With Acute Coronary Artery Syndrome
NCT00419471
COMPLETED
PHASE4
Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth
NCT02553161
COMPLETED
NA
Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder
NCT00109044
COMPLETED
PHASE3
Trial of Levomilnacipran in Geriatric Depression
NCT02466958
COMPLETED
PHASE4
Pattern Separation in Major Depressive Disorder
NCT07139834
NOT_YET_RECRUITING
PHASE1
Outcome Following Antidepressant Treatment on Possible Endo-Phenotypes for Major Depression
NCT00386841
COMPLETED
PHASE4
This is a Study to Determine the Antidepressant Effects of AZD6765
NCT00986479
COMPLETED
PHASE2
Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features
NCT00610506
COMPLETED
PHASE3
Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder
NCT00239954
UNKNOWN
PHASE3
Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder
NCT01024140
COMPLETED
NA
Positioning of Esketamine Treatment in the Real-world Management of Depression
NCT06103760
RECRUITING
PHASE4
Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder
NCT00432614
COMPLETED
PHASE3